Market research
0T22.F Onconova Therapeutics, Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 8M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 1.62
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 8M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 1.62
About
About Onconova Therapeutics, Inc
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Its novel proprietary multi-kinase inhibitor ON 123300 to target CDK4/6 and other tyrosine kinases. The company's product candidate oral rigosertib, which is in Phase 1 study of rigosertib in combination with a PD-1 inhibitor for patients with progressive K-Ras mutated non-small cell lung cancer; and in Phase 1b/2 for recessive dystrophic epidermolysis bullosa. In addition, it is involved in preclinical work investigating rigosertib in COVID-19. The company has a license agreement with SymBio Pharmaceuticals Limited; and license, development, and commercialization agreement with Pint International SA. Onconova Therapeutics, Inc. was founded in 1998 and is headquartered in Newtown, Pennsylvania.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 0T22.F discussion.
5 years, 4 months ago
Onconova Therapeutics, Inc is currently in a long term uptrend where the price is trading 29.5% above its 200 day moving average.
From a valuation standpoint, the stock is 45.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 715.3.
Onconova Therapeutics, Inc's total revenue rose by 90.0% to $57K since the same quarter in the previous year.
Its net income has dropped by 11.9% to $-6M since the same quarter in the previous year.
Finally, its free cash flow fell by 2.0% to $-5M since the same quarter in the previous year.
Based on the above factors, Onconova Therapeutics, Inc gets an overall score of 3/5.